The agency first approved Victoza to treat patients with type 2 diabetes in 2010. The drug may now be used to reduce the risk of cardiovascular events — like heart attacks and strokes — in this patient population.
The expanded approval stems from a clinical trial, which showed Victoza reduced the risk of cardiovascular events by 13 percent compared to a placebo.
More articles on supply chain:
7 drugmakers in the headlines
Gilead to acquire Kite Pharma for nearly $12B: 4 things to know
Blood supplier expects shortages in Texas amid Hurricane Harvey
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
